HenryCPitotMD

Oncology • Rochester, MN

Gastrointestinal Cancer

Associate Professor, Oncology, Mayo Medical School

Join to view full profile

Dr. Pitot is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pitot's full profile

Already have an account?

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Fax+1 507-284-1803

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1989 - 1992
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1986 - 1989
University of Wisconsin School of Medicine & Public HealthClass of 1986
University of Wisconsin, MadisonB.S., With Distinction, 1977 - 1981

Certifications & Licensure

MN State Medical License 1987 - 2025
WI State Medical License 2016 - 2025
IA State Medical License 1996 - 2005
FL State Medical License 1993 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Best Educators for Resident Education Mayo Clinic, 2008
General Clinical Research Center CR10 Award Mayo Clinic, 1994, 1998
Clinical Oncology Fellow American Cancer Society, 1990
Recognized for excellence in teaching Mayo Medical School, Mayo Clinic College of Medicine, 1989
Dean's List University of Wisconsin, Madison, 1977-1978, 1980
Join now to see all

Clinical Trials

Immediate Compared With Delayed Chemotherapy in Advanced Colorectal Cancer Without Signs or Symptoms of Disease Start of enrollment: 1994 Jul 15
Completed
Phase 3
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Start of enrollment: 1998 Oct 01
Completed
Phase 3
Dolastatin 10 in Treating Patients With Advanced Kidney Cancer Start of enrollment: 1999 Aug 01
Completed
Phase 2
Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer Start of enrollment: 2001 Apr 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan Start of enrollment: 2001 Apr 01
Completed
Phase 2
Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors Start of enrollment: 2002 Jun 13
Active, not recruiting
Phase 1
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System Start of enrollment: 2004 Jan 01
Terminated
Phase 2
Everolimus in Treating Patients With Stage IV Melanoma Start of enrollment: 2005 Apr 01
Completed
Phase 2
Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2006 Oct 01
Completed
Phase 2
A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies Start of enrollment: 2012 Apr 01
Withdrawn
Phase 1
Join now to see all

Publications & Presentations

PubMed

A Prospective Pilot Study of Pencil Beam Scanning Proton Radiation Therapy as a Component of Trimodality Therapy for Esophageal Cancer.
Christopher L Hallemeier, Kenneth W Merrell, Michelle A Neben-Wittich, Krishan R Jethwa, Harry H Yoon
Advances in Radiation Oncology. 2024-08-01
Resection of a Solitary Right Ventricular Metastasis in Oligorecurrent Hepatocellular Carcinoma.
Defne Gunes Ergi, Kyle W Klarich, Joseph A Dearani, Juan A Crestanello, Joseph J Maleszewski
Journal of Clinical Medicine. 2023-12-06
1 citations
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Sri Harsha Tella, Nathan Foster, Shi Qian, Tran Nguyen, Mitesh J Borad
The Oncologist. 2023-10-03

Journal Articles

Phase 2 study of bevicizumab plus erlotinib in patients with advanced hepatocellular cancer
Philip PA, Mahoney MR, Holen KD, Northfelt DW, Pitot HC, Picus J, Flynn PJ, Erlichman C, Cancer, 1/1/2011
Use of KW-2189, a DNA Minor Groove-Binding Agent, in Patients with Hepatocellular Carcinoma: A North Central Cancer Treatment Group (NCCTG) Phase II Clinical Trial
Alberts SR, Suman VJ, Pitot HC, Camoriano JK, Rubin J, Int J Gastrointest Cancer, 1/3/2008
The Phan/Yao article reviewed--Small steps forward in the land of small tumors
Hobday TJ, Pitot HC, Oncology, 1/1/2008
Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors
Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C, J Clin Oncol, 1/1/2002
Future directions in adjuvant therapy for stage III colon carcinoma
Pitot HC, Goldberg RM, Oncology, 1/1/2001
An NCCTG Phase II Trial of 9-Amino Camptothecin in Previously Untreated Patients With Measurable Metastatic Colorectal Cancer
Pitot H, Knost J, Mahoney M, Kugler J, Krook J, Hatfield A, Goldberg R, Sargent D, Cancer, 1/1/2000
The Damjanov/Meropol article reviewed
Pitot HC, Goldberg RM, Oncology, 1/1/2000
Treatment of advanced colorectal carcinoma
Pitot HC, Mayo Clinical Update, 1/1/1997
Join now to see all

Books/Book Chapters

Mayo Internal Medicine Board Review 2002-03
Chapter: Chapter 19: Oncology
Okuno SH, Pitot HCEditors: Thomas M, Habermann MD.Lippincott Williams & Wilkins2002
Mayo Internal Medicine Board Review 2000-01
Chapter: Chapter 18: Oncology
Okuno SH, Pitot HCEditors: Udaya BS, Prakash MD.Lippincott Williams & Wilkins2000
Cancer Chemotherapy and Biological Response Modifiers/13
Chapter: Breast Cancer
Pitot H, Loprinzi CLEditors: Pinedo HM, et al..Elsevier Science Publishers, Amsterdam1992

Lectures

Phase 1b extension study of cancer stemness inhibitor BB608 (napabucasin) administered in combination with FOLFIRI +/- bevacizumab (Bev) in patients (pts) with advance...
Chicago, IL - 1/1/2016
Association of androgen receptor variant 9 (AR-V9) mRNA expression levels in metastatic tissue with resistance to abiraterone acetate/prednisone (AA/P)
Chicago, IL - 1/1/2016
The association of JAK2 polymorphisms with prognosis in castration-resistant prostate cancer (CRPC)
San Francisco, CA - 1/1/2016
Association of androgen receptor V9 (ARV9) mRNA expression in metastatic tissue with early resistance to pre-chemotherapy abiraterone acetate/prednisone (AA/P)
San Francisco, CA - 1/1/2016
Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors
Chicago, IL - 1/1/2015
First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results
Chicago, IL - 1/1/2014
Association of germ-line genetic variation with failure of androgen ablation (AA) in hormone-sensitive advanced prostate cancer
Chicago, IL - 1/1/2013
A phase II study of combination epigenetic therapy in metastatic colorectal cancer (mCRC): A phase II consortium (P2C)/Stand Up 2 Cancer (SU2C) study
Chicago, IL - 1/1/2013
Association of germ-line genetic variation in the NK3 homeobox 1 gene with overall survival in advanced-stage castrate-resistant prostate cancer (CRPC)
Orlando, FL - 1/1/2013
PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and clinical activity of BMS-936559, an anti-PD-L1 antibody, in patients with solid tumors
Chicago, IL - 1/1/2012
Different Treatment Options for Metastatic Urothelial Carcinoma
Santiago, Chile - 1/12/2011
Neoadjuvant and Adjuvant Treatment of Bladder Cancer
Santiago, Chile - 1/12/2011
The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04
Chicago, IL - 1/1/2011
MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer
Orlando, FL - 1/1/2011
Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma
Orlando, FL - 1/1/2011
Phase I trial erlotinib, gemcitabine, and the hedgehog inhibitor, GDC-0449
Orlando, FL - 1/1/2011
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of NCCTG's phase III trials N9741 and N9841
Chicago, IL - 1/1/2011
Anti-B7-H1 Clinical Trial
Rochester, MN - 1/26/2010
Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients
Orlando, FL - 1/1/2009
Analysis of a phase I pharmacokinetic (PK)/food effect study of AT-101 in patients with advanced solid tumors
Orlando, FL - 1/1/2009
Liver Cancer
Rochester, MN - 1/1/2008
Management of Prostate Cancer
Kauai, HI - 1/1/2006
Symptom Management in Cancer Patients
Kauai, HI - 1/1/2006
N9841: A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) versus FOLFOX4 in Paitents with Advanced Colorectal Carcinoma Previously Treated with 5-Fluorour...
Orlando, FL - 1/1/2005
The IRB and Its Role in Protecting Human Subjects
Rochester, MN, 2003 - 1/1/2004
Join now to see all